Michael Raynor

Why organisations work with Michael Raynor

• He has built a quantitative case, across more than 25,000 companies and forty-five years of data, for what actually separates exceptional performers from the rest. Boards get an evidence base, not an opinion.
• His Strategy Paradox framework gives leadership teams a way to commit hard to a chosen direction while building real options against the futures that strategy could not foresee.
• He is one of the few strategy thinkers to have co-authored disruption theory’s primary sequel with Clayton Christensen and to have stress-tested it experimentally with Intel’s new venture group and MBA cohorts. The work is field-validated, not theoretical.
• Two decades of Deloitte client work in telecoms, pharma, medical devices, energy and media means the frameworks land in operational language, not academic abstraction.

Biography highlights

• Author of The Strategy Paradox, named one of BusinessWeek’s 10 Best Business Books of 2007 and a strategy+business top-five strategy pick.
• Co-author with Clayton M. Christensen of The Innovator’s Solution, a New York Times and Wall Street Journal bestseller.
• Co-author with Mumtaz Ahmed of The Three Rules: How Exceptional Companies Think, based on a five-year study of more than 25,000 US-listed companies.
• Sole author of The Innovator’s Manifesto: Deliberate Disruption for Transformational Growth, applying disruption theory to controlled experiments at Intel and across MBA programmes including Harvard.
• Doctorate from Harvard Business School, recognised with the Dively Award for research excellence; MBA with distinction from Ivey Business School.
• Associate Professor (Strategy) at Ivey Business School; long-tenured Deloitte advisor, including fifteen years as a Managing Director.

Biography

Most strategy is built on forecasts that turn out to be wrong. The interesting question is not whether forecasts will fail, but what a leadership team should do about that fact when it has to commit capital, talent and reputation to a single direction. This is the territory Michael Raynor has worked for over three decades, in research, in the boardroom and in print.

Raynor’s first major contribution was The Strategy Paradox, which argued that the same commitments that produce extraordinary success also produce catastrophic failure, and that managing strategic risk requires building real options into the corporate structure itself. The book was named one of BusinessWeek’s 10 Best Business Books of 2007 and a strategy+business top-five strategy pick. With Clayton Christensen he co-authored The Innovator’s Solution, a New York Times and Wall Street Journal bestseller and the principal sequel to The Innovator’s Dilemma.

The work that followed put the frameworks under empirical pressure. The Innovator’s Manifesto reported controlled experiments at Intel’s New Business Initiatives group and replications with 300+ MBA students at Harvard and elsewhere, showing measurable improvement in predictive accuracy when disruption theory was applied as a decision rule. The Three Rules, written with Mumtaz Ahmed, analysed more than 25,000 US-listed companies from 1966 to 2010 and identified 344 exceptional performers, distilling their behaviour to two priorities: better before cheaper, revenue before cost.

This is what brings Raynor into board conversations. He arrives with a doctorate from Harvard Business School (Dively Award for research excellence), an MBA with distinction from Ivey, more than two decades of Deloitte client work across pharma, telecoms, medical devices, energy and media, and a current Associate Professorship in Strategy at Ivey. The frameworks are tested, the language is direct, and the argument is consistently the same: serious organisations need a defensible answer to the question of how they will commit, and to what.

Key speaking topics

• Corporate strategy under uncertainty
• Strategic commitment and real options
• Disruptive innovation and growth
• Drivers of sustained superior corporate performance
• Innovation portfolio decisions
• Strategy execution at the board level

Ideal for

• Boards and CEOs setting multi-year strategic direction in industries where forecasts are unreliable
• Chief Strategy Officers and corporate development leaders sizing innovation portfolios and capital commitments
• Executive leadership teams in pharma, telecoms, energy, medical devices and media wrestling with disruption risk

Audience outcomes

• A direct argument for why strategic commitment is the source of risk, not its solution, and what that implies for the next planning cycle.
• The Better-before-Cheaper, Revenue-before-Cost decision rule as a working benchmark for everyday operating choices.
• A structured way to separate strategic uncertainty from operational uncertainty, and to push each to the right level of the organisation.
• An empirically grounded view of what 344 exceptional companies did differently over four decades, and how to test their behaviour against the audience’s own.